Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAbs have turnout to be fastest growing group of biotechnology-derived molecules in clinical trials. Driven by the growing application area pertaining to target disease viz. cancers, autoimmune disorders, infectious diseases, the monoclonal antibody market was valued over US$ 100 billion in 2017. Although various small molecule kinase inhibitors have been approved for targeting VEGF induced signaling, but the use of mAbs against VEGF have been established since FDA approval of Bevacizumab (Avastin, Genentech/Roche) in year 2004. Since, Avastin, FDA has approved ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea, Regeneron Pharma) both for cancer treatment and age related macular degradation (AMD). Therefore, use of mAbs in targeting VEGF induced angiogenesis in cancer, inflammation, arthritis and AMDs have tremendous potential in near future.
This report covers extensive analysis on:
Market segmentation by geography
- North America
- South America
- Europe
- Asia-Pacific
Key industry players
- Roche
- Novartis
- Sanofi
- Regeneron
- Bayer
- AstraZeneca
The report includes following key insights:
- In this report we discuss the novel technologies/methodologies used for production, purification, structural modifications and formulation of mAbs against VEGF ligands in various human pathologies using technology distribution based on IP analysis
- The report highlights the significant trends in efficacy, limitations and patient survival rate anti-VEGF antibodies therapy based on data available for Avastin, Lucentis, Eylea, Vanucizumab, Brolucizumab and hPV19
- This report showcases the competitive benchmarking of key industrial players like Roche, Sanofi, Novartis, Regeneron Pharma, AbbVie etc. in development of anti-VEGF antibodies from laboratory to clinical trials
- Product search and market forecast for trends in anti-VEGF mAbs will be extensively described
- The report will further include detailed description of anti-VEGF antibodies in clinical trials and their beneficial effects on targeted patients especially cancer and age related macular degradation, autoimmune diseases
- Report includes driving factors influencing global anti-VEGF mAbs market for year 2017-2022
- Detailed description of SWOT and PEST analysis in development of anti-VEGF antibody therapy
Table of Contents
Companies Mentioned
- Roche
- Novartis
- Sanofi
- Regeneron
- Bayer
- AbbVie
- Zymeworks
- Elan Pharma
- Five Prime Therapeutics
- Kymab Ltd
- Pfizer
- AstraZeneca
- Boehringer Ingelheim
Methodology
LOADING...